Articles from Inari Medical, Inc.

IRVINE, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other vascular diseases, announced today that its management team is scheduled to present at the J.P. Morgan Healthcare Conference on Wednesday, January 15 at 8:15 a.m. Pacific Time.

Reimbursement approval supports expanded access to effective, safe thrombus removal for patients suffering from deep vein thrombosis (DVT) in Japan

IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced it has entered into a joint venture with 6 Dimensions Capital (“6 Dimensions”) and its successor fund 120 Capital, and VFLO Medical (“VFLO”), a medical device platform incubated by 6 Dimensions and 120 Capital, to provide access to Inari’s innovative technology for patients with significant unmet needs in Greater China.

IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today its management team will present at the upcoming Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 10:00 AM Greenwich Mean Time / 5:00 AM Eastern Time.

Primary endpoint win driven by both hard clinical outcomes and hospital resource utilization

IRVINE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its third quarter ended September 30, 2024.

IRVINE, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- In recognition of World Thrombosis Day, Inari Medical, Inc. (NASDAQNARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced collaborative partnerships with the American Venous Forum (“AVF”) and the National Blood Clot Alliance (“NBCA”) on the DEFIANCE trial. This prospective, multinational, randomized controlled trial (“RCT”) will evaluate and compare clinical outcomes in patients with deep vein thrombosis (“DVT”) treated with Inari's ClotTriever System versus anticoagulation alone.

IRVINE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will host an analyst and investor meeting to discuss the PEERLESS study following its presentation at the Late-Breaking Clinical Trial Sessions at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C. The analyst and investor meeting will be held on Tuesday, October 29, 2024 at 11:00 a.m. Pacific Time / 2:00 p.m. Eastern Time.

IRVINE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its third quarter 2024 financial results on Monday, October 28, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

IRVINE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) --  Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that data from the PEERLESS trial will be presented by Dr. Wissam Jaber, Professor of Medicine at Emory University School of Medicine, during the Late-Breaking Clinical Trial Sessions at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C. The presentation will take place on October 29th.

IRVINE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the following investor conferences:

Mitch Hill to retire as Chief Financial Officer, to be succeeded by Kevin Strange in October 2024

IRVINE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its second quarter ended June 30, 2024.

IRVINE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its second quarter 2024 financial results on Tuesday, July 30, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

IRVINE, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it had filed a patent infringement lawsuit against Imperative Care, Inc. and Truvic Medical, Inc. (collectively, “Truvic”). The suit was filed in the United States District Court for the Northern District of California. Inari is seeking injunctive relief and damages for infringement.

IRVINE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today its management team will present at the upcoming Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024, at 11:20 AM Pacific Time.

IRVINE, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its first quarter ended March 31, 2024.

IRVINE, Calif., April 17, 2024 (GLOBE NEWSWIRE) --  Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its first quarter 2024 financial results on Tuesday, April 30, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the publication of its 2023 Ethos and Sustainability Report. The report highlights Inari’s commitment to its ethos and important corresponding environmental, social and governance (ESG) initiatives. The report can be found on Inari’s website here.

IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), today announced the appointment of Tim Benner as Senior Vice President of U.S. Sales and Dr. Andrew Niekamp as Vice President of Medical Affairs. Mr. Benner will be responsible for developing effective strategies across the company's multi-product sales platform and leading a high-performance commercial team to drive therapy penetration. Dr. Niekamp will be instrumental in advancing Inari’s mission to improve patient care through physician education and new device development.

Rates of Post Thrombotic Syndrome at two years were excellent and significantly lower than rates reported in historical Deep Vein Thrombosis trials

IRVINE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its fourth quarter and full year ended December 31, 2023.

IRVINE, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced preliminary unaudited fourth quarter and full year 2023 revenue and established its 2024 financial guidance.

IRVINE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced today its management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:45AM Pacific Time.

Clinical study randomizing up to 1,200 patients designed to help change guidelines in treating intermediate-risk Pulmonary Embolism (PE) patients globally

IRVINE, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the close of its acquisition of LimFlow S.A., a privately-held pioneer in limb salvage for patients with chronic limb-threatening ischemia (CLTI).

IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the following investor conferences:

IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its third quarter ended September 30, 2023.

Announces Q3 2023 Financial Results

IRVINE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its third quarter 2023 financial results on Wednesday, November 1, 2023. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

IRVINE, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the following investor conferences:

IRVINE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its second quarter ended June 30, 2023.

IRVINE, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the 43rd Annual Canaccord Growth Conference on Wednesday, August 9, 2023 at 4:00 p.m. Eastern Time at the InterContinental Boston Hotel in Boston, MA.

IRVINE, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its second quarter 2023 financial results on Wednesday, August 2, 2023. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

IRVINE, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced the launch of two new purpose-built products, the RevCore thrombectomy catheter, and the Triever16 Curve catheter.

IRVINE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the publication of its 2022 Ethos and Sustainability Report. The report highlights Inari’s commitment to its ethos and important corresponding environmental, social and governance (ESG) initiatives. The report can be found on Inari’s website here.

IRVINE, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced planned enrollment of the PEERLESS II trial, Inari’s third randomized controlled trial (RCT) in venous thromboembolism (VTE). The trial design was presented at the Society for Cardiovascular Angiography & Interventions (SCAI) 2023 Scientific Sessions.

IRVINE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its first quarter ended March 31, 2023.

IRVINE, Calif., May 02, 2023 (GLOBE NEWSWIRE) --  Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the Bank of America 2023 Healthcare Conference on Tuesday, May 9, 2023 at 3:00 p.m. Pacific Time at the Encore Hotel in Las Vegas.

IRVINE, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its first quarter 2023 financial results on Wednesday, May 3, 2023. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

IRVINE, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced positive results from the FLAME study in high-risk/massive pulmonary embolism (“PE”). The data was presented during the Late-Breaking Clinical and Investigative Horizons session at the 2023 ACC (American College of Cardiology) conference on March 5th by national Principal Investigator (PI) Mitchell Silver, DO, FACC, FVSM, RPVI, an interventional cardiologist and vascular medicine specialist at OhioHealth Riverside Methodist Hospital.

IRVINE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its fourth quarter and full year ended December 31, 2022.

IRVINE, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its fourth quarter and full year 2022 financial results on Monday, February 27, 2023. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

IRVINE, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will participate virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 14, 2023.

IRVINE, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that the first patient has been enrolled in DEFIANCE, a prospective randomized controlled trial (“RCT”) comparing the clinical outcomes of patients with iliofemoral deep vein thrombosis (“DVT”) treated with the ClotTriever System versus anticoagulation only. The trial is led by Principal Investigators: Dr. Xhorlina Marko, Interventional Radiologist at Beaumont Health; Dr. Steven Abramowitz, Chair of Vascular Surgery at MedStar Health; and Professor Stephen Black, MD, consultant vascular surgeon, Guy's and St. Thomas' Hospital, London.

IRVINE, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced preliminary unaudited fourth quarter and full year 2022 revenue and provided estimates for its 2023 guidance.

IRVINE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11th at 2:15PM Pacific Time.

IRVINE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum at the Westin NY Grand Central Hotel in New York on Thursday, November 17, 2022.

IRVINE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its third quarter ended September 30, 2022.

IRVINE, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive in-hospital and 30-day outcomes from the fully-enrolled 500-patient CLOUT registry. The company also reported positive results from a propensity-matched comparison of patients treated in the CLOUT registry versus patients treated with pharmacomechanical thrombolysis in ATTRACT, an NIH-sponsored randomized controlled trial. Both data sets were presented during a late breaking clinical trial session at the VEINS conference in Las Vegas, NV.

IRVINE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQNARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its third quarter 2022 financial results on Wednesday, November 2, 2022. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.